Patients with advanced bladder cancer treated with an immunosuppressant drug were a third less likely to see the disease return and more likely to survive for longer than patients who were given standard treatments, new research shows.
An expert who led the study said more patients could be cured if new treatments from the “game-changer” study become the new standard of care.
